Thermo Fisher Scientific Inc. has agreed to acquire Clario Holdings Inc., a provider of digital endpoint data solutions for clinical trials, in a cash transaction valued at $8.875 billion. The deal includes potential additional earnout and other payments contingent on future performance. Clario’s platform integrates clinical trial endpoint data from devices, sites, and patients, enabling pharmaceutical and biotechnology companies to digitally collect, manage, and analyze clinical evidence acr...